@Article{ecn.2009.0184,
AUTHOR = {Marco Locatelli, Leonardo Boiocchi, Stefano Ferrero, Filippo Martinelli Boneschi, Mario Zavanone, Samantha Pesce, Paola Allavena, Sergio Maria Gaini, Lorenzo Bello, Alberto Mantovani},
TITLE = {Human glioma tumors express high levels of the chemokine receptor CX3CR1},
JOURNAL = {European Cytokine Network},
VOLUME = {21},
YEAR = {2010},
NUMBER = {1},
PAGES = {27--33},
URL = {http://www.techscience.com/ECN/v21n1/65876},
ISSN = {1952-4005},
ABSTRACT = {The chemokine receptor CX3CR1 and its cognate ligand CX3CL1 (also known as fractalkine), are
involved in central nervous system pathophysiology, in particular, in the cross-talk between neurons and micro-glia.
It was therefore important to investigate the expression of CX3CR1 in gliomas, the most frequently occur-ring,
malignant brain tumors. In a consecutive series of 70 patients with primary, central nervous glial tumors,
CX3CR1 was highly expressed in tumor cells as assessed by RT-PCR mRNA and protein levels, and by immu-nohistochemistry,
while the corresponding normal cells were negative. Receptor immuno-positivity did not
correlate with histology, grade, chromosomal (1p,19q) deletion, or with methylation of the DNA repair gene
promoter MGMT (O6-methylguanine-DNA methyltransferase). Thus, CX3CR1 expression is a frequent event
in gliomas, irrespective of tumor classification and clinical severity. The molecular basis underlying CX3CR1
up-regulation and its functional biological significance remain to be determined.},
DOI = {10.1684/ecn.2009.0184}
}